Related Experiment Video
Updated: Aug 29, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Establishment of stable melanoma cell line expressing a novel gene, jpk, using a tetracycline-controlled gene
Byung-Gyu Kim1, Meang Sub Cheng, Hyoung Woo Park
1Department of Anatomy and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Sodaemoongu Shinchondong 134, Seoul 120-752, Korea.
Abstract:
Jpk, originally isolated as an associating factor with the position-specific regulatory element of Hoxa-7, was found to be toxic to Escherichia coli (1) and to F9 teratocarcinoma cells (2) when transiently transfected and expressed. To investigate the possibility of tumor gene therapy using Jpk, its effect was tested in B16F10 murine melanoma cells. Because Jpk reduces the viability of B16F10 cells when transiently expressed, the Jpk gene was cloned into a tetracycline-controlled gene expression vector, pRetro-On to circumvent the lethal effect in unwanted situations. The retroviral plasmid pRetroJpk purified from the packaging cell was infected into B16F10 melanoma cells and screened in the presence of puromycin. Out of a total of 53 stable clones selected with puromycin, two clones overexpressed Jpk at more than twice the level when induced by doxycycline, a tetracycline-derivative, which implies the amount of the Jpk exhibiting the toxicity is critical. Although these clones control only low levels of Jpk, overexpression of the established melanoma cell line may help us decipher the function of Jpk and apply it as a tumor therapeutic gene in the future.
Insights
The Jpk gene, toxic to cells, was engineered into a controllable system for potential cancer gene therapy. This approach aims to manage Jpk
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Background:
- Jpk protein identified as a regulatory factor for Hoxa-7.
- Transient expression of Jpk demonstrated toxicity in bacterial and cancer cell lines.
Purpose of the Study:
- Investigate Jpk's potential for tumor gene therapy.
- Develop a method to control Jpk expression and mitigate its toxicity.
Main Methods:
- Cloning Jpk into a tetracycline-controlled expression vector (pRetro-On).
- Generating stable B16F10 melanoma cell lines expressing Jpk via retroviral transduction.
- Selecting and screening puromycin-resistant clones for doxycycline-induced Jpk overexpression.
Main Results:
- Successfully created stable B16F10 cell lines with inducible Jpk expression.
- Identified clones with controlled, low-level Jpk overexpression.
- Confirmed that the level of Jpk expression is critical for its toxic effects.
Conclusions:
- Controlled Jpk expression is achievable, suggesting potential for therapeutic applications.
- Further research on Jpk overexpression in melanoma cells may elucidate its function.
- Jpk holds promise as a future tumor therapeutic gene.
